28.43
price up icon2.45%   0.68
after-market After Hours: 28.43
loading

Spyre Therapeutics Inc Stock (SYRE) Latest News

pulisher
09:10 AM

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Sold by Braidwell LP - MarketBeat

09:10 AM
pulisher
Nov 29, 2024

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation - AccessWire

Nov 29, 2024
pulisher
Nov 28, 2024

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation - AccessWire

Nov 28, 2024
pulisher
Nov 28, 2024

SYRESpyre Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 28, 2024
pulisher
Nov 27, 2024

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire

Nov 27, 2024
pulisher
Nov 26, 2024

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect - AccessWire

Nov 26, 2024
pulisher
Nov 25, 2024

Spyre Therapeutics’ $200 Million Common Stock Offering - Global Legal Chronicle

Nov 25, 2024
pulisher
Nov 25, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - PR Newswire

Nov 25, 2024
pulisher
Nov 25, 2024

Spyre Therapeutics to Present at Evercore ISI HealthCONx Conference | IBD Treatment Updates | SYRE Stock News - StockTitan

Nov 25, 2024
pulisher
Nov 25, 2024

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Stockholders to Connect - AccessWire

Nov 25, 2024
pulisher
Nov 24, 2024

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire

Nov 24, 2024
pulisher
Nov 22, 2024

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation - AccessWire

Nov 22, 2024
pulisher
Nov 21, 2024

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation - AccessWire

Nov 21, 2024
pulisher
Nov 20, 2024

First Week of January 2025 Options Trading For Spyre Therapeutics - Nasdaq

Nov 20, 2024
pulisher
Nov 20, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out - AccessWire

Nov 20, 2024
pulisher
Nov 19, 2024

Spyre Therapeutics Prices of $200 Million Public Offering of Common Stock - citybiz

Nov 19, 2024
pulisher
Nov 19, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap DownShould You Sell? - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Spyre Therapeutics announces pricing of $200 million public offering of common stock - MSN

Nov 19, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics Launches $200M Public Offering for IBD Treatment Development | SYRE Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - PR Newswire

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics revises net loss per share calculations - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics launches $200 million public offering - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics Launches $200M Public Stock Offering for IBD Drug Development | SYRE Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 15, 2024

Wedbush Expects Weaker Earnings for Spyre Therapeutics - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Perceptive Advisors LLC Reduces Stake in Spyre Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

SYRE Crosses Below Key Moving Average Level - Nasdaq

Nov 14, 2024
pulisher
Nov 14, 2024

Avoro Capital Advisors LLC Adjusts Stake in Spyre Therapeutics I - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Deep Track Capital, LP Adjusts Stake in Spyre Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Robert W. Baird Increases Spyre Therapeutics (NASDAQ:SYRE) Price Target to $65.00 - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Spyre reports promising Phase 1 results for IBD therapy By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Acquires Additional Shares in Spyre Therapeutics Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Equities Analysts Offer Predictions for SYRE Q1 Earnings - Defense World

Nov 12, 2024
pulisher
Nov 12, 2024

Spyre reports promising Phase 1 results for IBD therapy - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

Spyre's IBD Drug Shows Breakthrough 90-Day Half-Life in Phase 1 Trial, 4x Better Than Standard | SYRE Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $46.43 Average PT from Brokerages - Defense World

Nov 12, 2024
pulisher
Nov 11, 2024

Spyre Therapeutics to Reveal Key IBD Drug Trial Data: SPY001 Results Coming Nov 12 | SYRE Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 11, 2024

Q1 Earnings Estimate for SYRE Issued By Wedbush - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE) - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Spyre Therapeutics director Jeffrey Albers sells $246,312 in stock - Investing.com India

Nov 09, 2024
pulisher
Nov 09, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Analysts - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Spyre Therapeutics director Jeffrey Albers sells $246,312 in stock By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 08, 2024

Spyre Therapeutics: Q3 Earnings Snapshot - Thehour.com

Nov 08, 2024
pulisher
Nov 08, 2024

Spyre Therapeutics Advances IBD Treatment Pipeline - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

Nov 07, 2024
pulisher
Nov 03, 2024

292,569 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Emerald Advisers LLC - MarketBeat

Nov 03, 2024
pulisher
Nov 01, 2024

Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire

Nov 01, 2024
pulisher
Oct 30, 2024

Spyre Therapeutics to Participate in Upcoming November Investor Conferences - Yahoo Finance

Oct 30, 2024
pulisher
Oct 29, 2024

Spyre Therapeutics (NASDAQ:SYRE) Price Target Increased to $65.00 by Analysts at Guggenheim - Defense World

Oct 29, 2024
pulisher
Oct 29, 2024

Spyre Therapeutics director sells shares worth $10,929 - Investing.com India

Oct 29, 2024
pulisher
Oct 28, 2024

Spyre Therapeutics director sells shares worth $10,929 By Investing.com - Investing.com South Africa

Oct 28, 2024
$21.50
price up icon 1.61%
$74.59
price down icon 1.14%
$370.49
price down icon 2.02%
$43.06
price down icon 0.76%
$215.00
price up icon 4.29%
$118.39
price down icon 1.93%
Cap:     |  Volume (24h):